[CAS NO. 1097917-15-1] ASP3026
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1097917-15-1]
Store
Catalog
SLK-S8054
Brand
Selleck
CAS
1097917-15-1
DESCRIPTION [1097917-15-1]
Overview
| MDL | MFCD21609265 |
|---|---|
| Molecular Weight | 580.74 |
| Molecular Formula | C29H40N8O3S |
| SMILES | O=S(C1=CC=CC=C1NC2=NC=NC(NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3OC)=N2)(C(C)C)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7219 mL | 8.6097 mL | 17.2194 mL |
| 5 mM | 0.3444 mL | 1.7219 mL | 3.4439 mL |
| 10 mM | 0.1722 mL | 0.8610 mL | 1.7219 mL |
| 50 mM | - | - | - |
Description
ASP3026 is a novel and selective inhibitor for with of 3.5 nM. Phase 1.
Features
ALK-selective inhibitor that has been tested in Phase I clinical trials for treatment of solid tumors and B-cell lymphoma.
Targets
| ALK [1] |
| 3.5 nM |
In vitro
ASP3026 shows more selective ALK inhibition in a Tyr-kinase panel than PF02341066. ASP3026 inhibits the growth of NCI-H2228, a human NSCLC tumor cell line endogenously expressing EML4-ALK variant 3, with an IC50 value of 64.8 nM.
In vivo
ASP3026, administered to mice bearing subcutaneous NCI-H2228 tumor xenografts as twice daily oral dosing for 14 days, induces dose dependent anti-tumor effects starting at 1 mg/kg with strong regression at 10, 30 and 100 mg/kg.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.